Editas Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced its participation in three major healthcare investor conferences. The company will be featured in fireside chat sessions at Guggenheim's Inaugural Healthcare Innovation Conference on November 12 at 4:00 p.m. ET in Boston, the Stifel 2024 Healthcare Conference on November 19 at 1:50 p.m. ET in New York, and the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 1:20 p.m. ET in Coral Gables. Live webcasts will be available on the company's website, with replays accessible for approximately 30 days after each event.

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

• Guggenheim’s Inaugural Healthcare Innovation Conference
  Format: Fireside Chat
  Date: Tuesday, November 12
  Time: 4:00 p.m. ET
  Location: Boston, MA

• Stifel 2024 Healthcare Conference
  Format: Fireside Chat
  Date: Tuesday, November 19
  Time: 1:50 p.m. ET
  Location: New York, NY

• 7th Annual Evercore ISI HealthCONx Conference
  Format: Fireside Chat
  Date: Tuesday, December 3
  Time: 1:20 p.m. ET
  Location: Coral Gables, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

FAQ

What investor conferences is Editas Medicine (EDIT) attending in November and December 2024?

Editas Medicine will participate in three conferences: Guggenheim's Inaugural Healthcare Innovation Conference (Nov 12), Stifel 2024 Healthcare Conference (Nov 19), and the 7th Annual Evercore ISI HealthCONx Conference (Dec 3).

How can investors watch Editas Medicine's (EDIT) conference presentations?

Investors can watch live webcasts of the presentations through the 'Investors' section of Editas Medicine's website at www.editasmedicine.com. Archived replays will be available for approximately 30 days after each event.

What is the format of Editas Medicine's (EDIT) presentations at the upcoming conferences?

All three presentations will be in a fireside chat format at their respective conferences.